IR Department provides expert consulting services across the areas of investor relations, public relations, marketing and communications. Our clients treat us as an outsourced management team – we're there for both strategy and execution. We like to do what we say we're going to do – delivering to brief and reporting to clients along the way, so that they can measure our collective success.
Anatara Lifesciences Ltd (ASX:ANR) today released its Appendix 4E for the period ending 30th June 2016.
Chairman & CEO, Dr Mel Bridges said, "We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch," Dr Bridges added.
Anatara Lifesciences (ASX:ANR) releases its latest institutional roadshow presentation and market update. This week CEO & Chairman Dr Mel Bridges and Co-Founder and Chief Scientific Officer (CSO) Dr Tracey Mynott will be conducting a roadshow updating existing and potential new institutional investors and analysts.
Anatara Lifesciences (ASX:ANR) announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.
Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges presented at the Finance News Network CEO Conference and the Gold Coast Investment Showcase this week.
